Lilly’s tirzepatide brings down body weight in people with type 2 diabetes
Lilly's Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes.
This was achieved after 40 weeks of...
New inflammatory disease found by researchers
Researchers from National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Human Genome Research Institute (NHGRI), and National...
NeuroRx starts Phase 2/3 study of inhaled ZYESAMI
NeuroRx, Inc. has announced initiation of a Phase 2/3 clinical trial investigating the role of inhaled ZYESAMI (aviptadil).
The trial is being done for the...
